GlassScriptPhysician profile
Matthew R Cox
NPI 1407017940
$9,740.79
in general payments reported to CMS, 2019-2025
43 companies · $1,304 in 2025
The $1,304 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,447 · 2020: $885 · 2021: $1,232 · 2022: $1,830 · 2023: $1,737 · 2024: $1,306 · 2025: $1,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,347.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,178.97 | 2019-2025 | |
| Amgen INC. | $693.73 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $692.22 | 2021-2025 | Verquvo |
| Pfizer INC. | $691.15 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $671.96 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $651.17 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $636.66 | 2019-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $610.68 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $583.37 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Medtronic, INC. | $297.03 | 2021-2025 | Corevalve Evolut R, Cobalt Dr Mri Surescan, Amplia Mri Quad Crt-D Surescan |
| Sanofi-Aventis U.S. LLC | $291.06 | 2019-2023 | |
| Abbott Laboratories | $285.17 | 2019-2024 | Aveir |
| Edwards Lifesciences Corporation | $269.86 | 2020-2025 | Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $197.38 | 2019-2025 | Watchman Flx, Watchman |
| Regeneron Healthcare Solutions, INC. | $196.69 | 2019-2023 | Evkeeza |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $194.53 | 2021-2024 | |
| Scpharmaceuticals INC. | $154.23 | 2023-2025 | |
| Amarin Pharma, INC. | $150.14 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $138.91 | 2019-2025 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $99.72 | 2023-2024 | Inpefa |
| Esperion Therapeutics, INC. | $98.97 | 2021-2024 | Nexletol |
| Impulse Dynamics (USA) INC. | $90.76 | 2022-2025 | Optimizer, Optimizer |
| Baxter Healthcare | $88.92 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Lundbeck LLC | $86.58 | 2019 | |
| Bridgebio Pharma, INC. | $81.87 | 2025 | Attruby |
| Kowa Pharmaceuticals America, INC. | $65.83 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $65.35 | 2022-2025 | Onpattro |
| Kiniksa Pharmaceuticals International, Plc | $59.24 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $49.99 | 2024 | Zio Monitor, Zio Xt Patch |
| Inspire Medical Systems, INC. | $41.25 | 2023-2024 | Inspire |
| Itamar Medical INC | $35.00 | 2025 | Watchpatone |
| Medtronic Vascular, INC. | $34.32 | 2019-2020 | |
| Ge Healthcare | $34.11 | 2021 | |
| Amryt Pharma Holdings LTD | $32.44 | 2021 | |
| Lilly USA, LLC | $32.40 | 2025 | Mounjaro, Zepbound |
| Kiniksa Pharmaceuticals, LTD. | $31.79 | 2022-2023 | Arcalyst |
| Cvrx, INC. | $29.88 | 2024 | Barostim Neo System |
| Astellas Pharma US INC | $19.20 | 2020 | |
| Chiesi USA, INC. | $18.51 | 2025 | Juxtapid |
| Gilead Sciences, INC. | $16.91 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $16.47 | 2025 | Uptravi, Opsumit |
| Bardy Diagnostics, INC. | $15.00 | 2021 | |
| Biotronik INC. | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.